"Neutralization Tests" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
| Descriptor ID |
D009500
|
| MeSH Number(s) |
E01.370.225.812.735.550 E05.200.812.735.550 E05.478.594.760.550
|
| Concept/Terms |
Neutralization Tests- Neutralization Tests
- Neutralization Test
- Test, Neutralization
- Tests, Neutralization
|
Below are MeSH descriptors whose meaning is more general than "Neutralization Tests".
Below are MeSH descriptors whose meaning is more specific than "Neutralization Tests".
This graph shows the total number of publications written about "Neutralization Tests" by people in this website by year, and whether "Neutralization Tests" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 4 | 5 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 6 | 7 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 4 | 4 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 8 | 10 |
| 2022 | 0 | 4 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neutralization Tests" by people in Profiles.
-
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive Fc?RIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. J Virol. 2024 Jul 23; 98(7):e0067824.
-
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. Virol J. 2022 09 07; 19(1):143.
-
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. J Virol. 2022 08 10; 96(15):e0055822.
-
Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
-
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep Med. 2022 02 15; 3(2):100510.
-
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022 02; 602(7898):654-656.
-
Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission. J Virol. 2022 02 23; 96(4):e0193421.
-
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies. J Virol. 2022 01 26; 96(2):e0164321.
-
Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth. Front Immunol. 2021; 12:734110.
-
HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Front Immunol. 2021; 12:733958.